NEWARK, Del, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The hypercalcemia treatment market is expected to reach a significant worth of nearly US$ 18.07 billion in the current year 2023. Over the foreseeable years, this emerging healthcare services business is expected to develop at a remarkable CAGR of 11.8%. Expanding at this promising growth rate, the overall market could potentially reach a value of US$ 55.07 billion by 2033.
Advances in medical research have resulted in a better knowledge of underlying causes of hypercalcemia allowing businesses to develop effective and tailored treatment options. The expanded information base has resulted in a generational transition toward specialized treatment alternatives and services further supporting the market growth of hypercalcemia management services.
Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-1320
The world’s aging population has considerably increased hypercalcemia instances as they are vulnerable to high calcium levels such as malignancies, renal problems, and hormone abnormalities. As Elevated calcium levels in the blood become increasingly common, the need for hypercalcemia treatment demanding specific management services is expected to rise steadily.
Many adverse effects associated with medications recommended for hyperparathyroidism could be a prominent setback for the global hypercalcemia treatment market. In particular, the side effects associated with drugs such as Cinacalcet, a calcimimetic agent, include diarrhea, myalgia, nausea, vomiting, weakness, and abdominal pain.
Key Takeaways from the Hypercalcemia Treatment Market:
- The adoption of hypercalcemia treatment is high in North America as the region recorded 45.7% of the global revenue in 2022. The United States with 39.7% global market share is the main reason for the dominance of this region.
- Countries in Europe together contributed almost 26.7% of the global market revenue in 2022. Germany was the leading country with a 6.6% market share that year.
- The United Kingdom is projected to expand at 10.2% CAGR through 2033.
- China is poised to witness a 13.3% CAGR through 2033 in the Asia Pacific region.
- India is anticipated to follow China with an 11.8% CAGR through 2033.
- Biphosphonates led the global industry with a market share of around 70.1% in 2022 according to our market survey.
Businesses providing hypercalcemia treatment services are actively attempting to enhance their market positions through approvals, partnerships, and agreements with regional healthcare institutions. Also, the introduction of new drugs and products has strengthened manufacturer's goal to capitalize on market share and grab a sizable market share.” – According to Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Competitive Landscape for the Hypercalcemia Treatment Market:
Rising healthcare spending in many countries is creating a favorable atmosphere for the expansion of hypercalcemia pharmaceutical industries. Governments and healthcare institutes are both realizing the necessity of tackling this disease, and are investing money in research, development, and access hypercalcemia drug market.
Click Here to Buy Your Full Report! https://www.futuremarketinsights.com/checkout/1320
Recent Developments in the Hypercalcemia Treatment Market:
Sunovian Pharmaceuticals Company established a collaborative development and partnership program with Otsuka Pharmaceutical Company in September 2021. It was part of an endeavor to strengthen research and development operations regarding hypercalcemia conditions and to manufacture innovative therapeutic ingredients.
The pharmaceutical company Bayer in Germany applied for the USA FDA priority evaluation of their new medication Application for Finerenone in January 2021. This new medication is intended to treat patients with chronic kidney disease and associated Type 2 diabetes as well.
Top Key Companies Profiled in the Hypercalcemia Treatment Market:
- Amgen Inc.
- Pfizer Inc.
- Mylan N. V.
- Sunovion
- Procter And Gamble
- Apotex Corporation
- Genentech, Inc.
- Novartis AG
- Bayer AG
- Hoffmann La Roche
- Atnahs Pharma
- Cipla Inc.
- Sun Pharmaceuticals Industries Ltd
- Dr. Reddy’s Laboratories
- Aurobindo Pharma Limited
Click Here to Request Methodology! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1320
Key Market Segments Covered In Hypercalcemia Treatment Industry Research:
By Product:
- Bisphosphonates
- Clodronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
By Distribution Channel:
- Hospitals
- Clinics
- Independent Pharmacy & Drug Stores
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
Have a Look at the Related Report of the Hypercalcemia Treatment Market:
- Point-Of-Care Breathalyzer Market is anticipated to be valued at US$ 385.7 Million in 2022, forecast a CAGR of 5.5% to be valued at US$ 658.9 Million from 2022 to 2032.
- Point-of-care Molecular Diagnostics Market is estimated to capture a valuation of US$ 4.4 billion in 2023 and is rising to US$ 11.1 billion by 2033. The market is predicted at a CAGR of 9.7% during the forecast period.
- Non-Hospital-Based Point-Of-Care Diagnostic Products Market is likely rise to a US$ 12.9 billion valuation in 2022. The demand for non-hospital-based point-of-care diagnostic products is estimated to reach US$ 33.6 Billion by 2032
- Point-of-care Cholesterol Monitoring Device Market was valued at US$ 428.8 Mn in 2021 and is expected to reach US$ 514.7 Mn by 2028, finds Future Market Insights (FMI) in a recent market survey.
- Point-of-Care Diagnostics Market is expected to grow at a CAGR of 6.8%. The market value is projected to increase from US$ 38.7 Billion in 2023 to US$ 74.8 Billion by 2033.
Authored by:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
